Syros Pharmaceuticals (NASDAQ:SYRS) Downgraded to Sell at StockNews.com

StockNews.com downgraded shares of Syros Pharmaceuticals (NASDAQ:SYRS) from a hold rating to a sell rating in a research report released on Wednesday morning.

Other equities analysts have also issued research reports about the company. HC Wainwright restated a buy rating and set a $15.00 price objective on shares of Syros Pharmaceuticals in a research note on Monday, April 1st. Piper Sandler reiterated an overweight rating and issued a $13.00 price target on shares of Syros Pharmaceuticals in a research note on Wednesday, April 3rd.

Syros Pharmaceuticals Stock Performance

Syros Pharmaceuticals stock opened at $5.11 on Wednesday. The stock’s fifty day moving average price is $6.34 and its two-hundred day moving average price is $5.19. Syros Pharmaceuticals has a one year low of $2.09 and a one year high of $8.17. The company has a debt-to-equity ratio of 2.07, a quick ratio of 3.95 and a current ratio of 3.95.

Institutional Investors Weigh In On Syros Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the company. Clarius Group LLC bought a new stake in Syros Pharmaceuticals during the 3rd quarter worth $74,000. CHI Advisors LLC grew its position in Syros Pharmaceuticals by 69.3% during the 3rd quarter. CHI Advisors LLC now owns 1,299,359 shares of the company’s stock worth $5,119,000 after acquiring an additional 531,914 shares during the last quarter. Assenagon Asset Management S.A. lifted its holdings in Syros Pharmaceuticals by 142.2% during the 3rd quarter. Assenagon Asset Management S.A. now owns 25,130 shares of the company’s stock worth $99,000 after buying an additional 14,754 shares during the period. Avidity Partners Management LP lifted its holdings in Syros Pharmaceuticals by 8.0% during the 3rd quarter. Avidity Partners Management LP now owns 1,581,142 shares of the company’s stock worth $6,246,000 after buying an additional 117,108 shares during the period. Finally, Two Sigma Investments LP lifted its holdings in Syros Pharmaceuticals by 30.0% during the 1st quarter. Two Sigma Investments LP now owns 13,600 shares of the company’s stock worth $36,000 after buying an additional 3,139 shares during the period. Institutional investors own 91.47% of the company’s stock.

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.